



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Wednesday May 15, 2024

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
TLXAP	SHARE RIGHTS	35,000	13/05/2024
TLXAO	SHARE APPRECIATION RIGHTS	3,095,526	13/05/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

15/5/2024



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

TLXAP : SHARE RIGHTS

Date the +securities the subject of this notification were issued

13/5/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Richard Valeix	Richard Valeix	35,000

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Any other information the entity wishes to provide about the +securities the subject of this notification

The second tranche of Performance Share Rights (exercise price: nil) granted to Richard Valeix (CCO) as part of his sign on to the CCO role as detailed in section 5.4.1 of the 2023 Remuneration report. Vesting is subject to achievement of the performance conditions of the 2024 Long Term Variable Remuneration (LTVR).

Issue details

Number of +securities

35,000

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

13/5/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Darren Smith	Darren Smith	50,874
Richard Valeix	Richard Valeix	60,358
David Cade	David Cade	49,461
Darren Patti	Darren Patti	66,838

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights (PSARs) (exercise price: \$11.94) granted to Telix employees as 2024 Long Term Variable Remuneration (LTVR) as part of Total Target Remuneration Package for 2024. This includes Long Term Incentive PSARs granted to Darren Patti in relation to his role prior to being appointed as Group Chief Operating Officer. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2024-2026. For further details refer to the Remuneration report in Telix's 2023 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

Issue details

Number of +securities

3,095,526



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	330,455,778

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	2,523,720
TLXAP : SHARE RIGHTS	1,230,000
TLXAO : SHARE APPRECIATION RIGHTS	11,212,780
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	584,492
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	685,510
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13